Ann: CYP Receives Favourable Advice from UK Regulatory Authority, page-25

First 25 Last

Share
Profile

Follow
QiQi

1,070 Posts.

546

28/01/16

21:48

Post #: 16889772
Share

Originally posted by philby ↑

just to finish cos i was in a rush then.
Its no big surprise that the first LOI's are with the likes of a Japanese company and this particular german company.
why.
1. the Japanese are at the top in understanding IPSc's remember, japanese scientist won the nobel prize in relation to IPscs.. they know the limitations on a commercial scale of using either allogeneic or autologous i.e from human donors, regience even state as much on their website in their LOI announcment..cymerus cures the pipeline probelm...so regience are not cutting any corners and probably going to straight to the required commercial science needed for mass therapies...Cymerus!!

2 Apceth although the germans are behind the Japanese and americans in terms of stem cell research they have clearly got to a point with their research where they have been scratching their heads as to overcome the pipeline issue..how do we make this stuff cheaply enough and standardised...aha..along comes cymerus..must have been like xmas..imagine spending all that research money to come to an expensive dead end..and low and behold.....Cymerus.
Apceth as we know are backed by very wealthy doctors who are keener on making their cancer system work commercially ( theres even a space for us on their corporate presesention titled' other'..i think page 4...kidding nut it is there) than playing market games...
truth is most therapeutic companies will comes to us...
unless as i have said before someone finds another way of making loads of cheap frogspawn in a standardised manner.
I hope that if that time we have all sold out for in excess of both cdi 307 mill and that other one mentioned by unbelievable..cant remember name but 400 mill.
at some point as the scientist sign on the dotted line thru necessity the money boys will pile in.
soon i think..haha!!!!

Expand

...by the sounds of it then, MSB should bring CYP into their fold.
Whether through a takeover (if at all realistic), merger or to work cooperatively.

Last edited by QiQi: 28/01/16

CYP Price at posting: 37.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 1 more message in this thread...

First 25 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 27.0¢		Change -0.005(1.82%)		Mkt cap ! $48.78M

Open	High	Low	Value	Volume
27.5¢	28.5¢	26.5¢	$71.17K	257.3K

Buyers (Bids)

No.	Vol.	Price($)
4	145786	27.0¢

Sellers (Offers)

Price($)	Vol.	No.
28.0¢	15000	1

View Market Depth

No.	Vol.	Price($)
4	145786	0.270
3	12000	0.265
2	105000	0.260
3	14799	0.250
1	10000	0.245

Price($)	Vol.	No.
0.280	15000	1
0.290	36000	1
0.295	25028	2
0.300	72500	2
0.305	29140	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

CYP (ASX) Chart

Ann: CYP Receives Favourable Advice from UK Regulatory Authority, page-25

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: CYP Receives Favourable Advice from UK Regulatory Authority, page-25

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News